Premium
Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura
Author(s) -
Stouffer George A.,
Hirmerova Jana,
Moll Stephan,
Rubery Bryon,
Napoli Mark,
Ohman E. Magnus,
Simpson Ross
Publication year - 2004
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10799
Subject(s) - medicine , percutaneous coronary intervention , thrombocytopenic purpura , clopidogrel , aspirin , restenosis , percutaneous , eptifibatide , surgery , cardiology , interventional cardiology , stent , platelet , myocardial infarction
The appropriate regimen of platelet inhibitors that should be used in patients with immune thrombocytopenia purpura (ITP; formerly called idiopathic thrombocytopenic purpura) who are undergoing percutaneous coronary intervention is unclear. We report the case of a patient with ITP who underwent two separate coronary interventions. The first involved the use of aspirin and a cutting balloon to treat obstructive disease of the left circumflex. When the patient presented with restenosis, he received eptifibatide, clopidogrel, and an intracoronary stent. He is currently 16 months removed from his second procedure and remains physically active without any anginal symptoms. Percutaneous revascularization in patients with ITP remains a challenge and this therapeutic approach, while ultimately successful in the patient, requires further validation. Catheter Cardiovasc Interv 2004;61:364–367. © 2004 Wiley‐Liss, Inc.